Pallas Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Pallas Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.07M	Sell	2,680 -542	-17%	-$415K	0.08%	190
2025 Q4	$2.49M	Buy	3,222 +880	+38%	+$598K	0.08%	189
2025 Q3	$1.32M	Buy	+2,342	New	+$1.32M	0.05%	278
2025 Q2	–	Sell	-671	Closed	-$426K	–	916
2025 Q1	$426K	Buy	+671	New	+$462K	0.02%	514
2022 Q1	–	Sell	-531	Closed	-$330K	–	284
2021 Q4	$330K	Sell	531 -233	-30%	-$143K	0.04%	241
2021 Q3	$498K	Buy	+764	New	+$474K	0.05%	228

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pallas Capital Advisors's REGN Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q1 2026, selling an estimated $415K and leaving 2,680 shares worth $2.07M. The position accounts for 0.08% of the portfolio, ranked #190.

Pallas Capital Advisors first reported a position in REGN in Q3 2021 and has held it in 6 quarters since. The position peaked at $2.49M in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Pallas Capital Advisors held 2,680 shares of Regeneron Pharmaceuticals worth $2.07M as of Q1 2026.
Pallas Capital Advisors sold 542 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $415K.
Regeneron Pharmaceuticals made up 0.08% of Pallas Capital Advisors's portfolio in Q1 2026, its #190 holding.
Pallas Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 6 quarters since.
Pallas Capital Advisors's Regeneron Pharmaceuticals position peaked at $2.49M in Q4 2025.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.